v3.26.1
Revenue - Schedule of Disaggregation of Revenue by Product (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Disaggregation of Revenue [Line Items]        
Revenue $ 22,974 $ 15,558 $ 42,773 $ 28,286
U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 14,413 10,814 26,532 19,304
Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 8,561 4,743 16,241 8,983
Cardiometabolic Health        
Disaggregation of Revenue [Line Items]        
Revenue 18,353 11,343 34,113 20,551
Cardiometabolic Health | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 11,742 8,363 21,666 14,940
Cardiometabolic Health | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 6,611 2,980 12,447 5,611
Mounjaro        
Disaggregation of Revenue [Line Items]        
Revenue 9,943 5,199 18,605 9,041
Mounjaro | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 4,791 3,302 9,024 5,958
Mounjaro | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 5,152 1,897 9,582 3,083
Zepbound        
Disaggregation of Revenue [Line Items]        
Revenue 4,928 3,381 9,088 5,693
Zepbound | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 4,873 3,380 9,006 5,685
Zepbound | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 55 2 81 8
Jardiance        
Disaggregation of Revenue [Line Items]        
Revenue 1,232 690 2,346 1,704
Jardiance | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 616 382 1,128 692
Jardiance | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 615 308 1,218 1,012
Trulicity        
Disaggregation of Revenue [Line Items]        
Revenue 1,219 1,092 2,138 2,187
Trulicity | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 908 744 1,508 1,514
Trulicity | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 312 348 630 673
Other cardiometabolic health        
Disaggregation of Revenue [Line Items]        
Revenue 1,031 980 1,936 1,925
Other cardiometabolic health | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 554 556 1,000 1,091
Other cardiometabolic health | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 477 425 936 835
Oncology        
Disaggregation of Revenue [Line Items]        
Revenue 2,570 2,414 4,838 4,361
Oncology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 1,473 1,419 2,700 2,465
Oncology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 1,097 994 2,138 1,896
Verzenio        
Disaggregation of Revenue [Line Items]        
Revenue 1,474 1,489 2,776 2,648
Verzenio | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 845 929 1,551 1,587
Verzenio | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 629 560 1,224 1,062
Other oncology        
Disaggregation of Revenue [Line Items]        
Revenue 1,096 924 2,062 1,713
Other oncology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 628 490 1,149 879
Other oncology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 468 434 914 835
Immunology        
Disaggregation of Revenue [Line Items]        
Revenue 1,417 1,256 2,620 2,344
Immunology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 790 701 1,409 1,279
Immunology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 627 555 1,211 1,065
Taltz        
Disaggregation of Revenue [Line Items]        
Revenue 856 848 1,588 1,610
Taltz | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 539 549 956 1,025
Taltz | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 317 299 632 584
Other immunology        
Disaggregation of Revenue [Line Items]        
Revenue 561 408 1,032 734
Other immunology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 251 152 453 254
Other immunology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 310 256 579 480
Neuroscience        
Disaggregation of Revenue [Line Items]        
Revenue 429 344 811 616
Neuroscience | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 325 248 617 437
Neuroscience | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 104 96 194 179
Other        
Disaggregation of Revenue [Line Items]        
Revenue 205 202 392 414
Other | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 84 83 140 182
Other | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue $ 122 $ 119 $ 252 $ 232